METABOLISM OF DAPSONE TO ITS HYDROXYLAMINE BY CYP2E1 IN-VITRO AND IN-VIVO

被引:87
作者
MITRA, AK
THUMMEL, KE
KALHORN, TF
KHARASCH, ED
UNADKAT, JD
SLATTERY, JT
机构
[1] UNIV WASHINGTON, DEPT PHARMACEUT, SEATTLE, WA 98195 USA
[2] UNIV WASHINGTON, DEPT ANESTHESIOL, SEATTLE, WA 98195 USA
[3] UNIV WASHINGTON, DEPT MED CHEM, SEATTLE, WA 98195 USA
关键词
D O I
10.1016/0009-9236(95)90176-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dapsone toxicity is putatively initiated by formation of a hydroxylamine metabolite by cytochromes P450. In human liver microsomes, the kinetics of P450-catalyzed N-oxidation of dapsone were biphasic, with the Michaelis-Menten constants of 0.14 +/- 0.05 and 0.004 +/- 0.003 mmol/L and the respective maximum velocities of 1.3 +/- 0.1 and 0.13 +/- 0.04 nmol/mg protein/min (mean +/- SEM). Troleandomycin (40 mu mol/L) inhibited hydroxylamine formation at 100 mu mol/L dapsone by 50%; diethyldithiocarbamate (150 mu mol/L) and tolbutamide (400 mu mol/L) inhibited at 5 mu mol/L dapsone by 50% and 20%, respectively, suggesting that the low-affinity isozyme is CYP3A4 and the high-affinity isozymes are 2E1 and 2C. Disulfiram, 500 mg, 18 hours before a 100 mg oral dose of dapsone in healthy volunteers, diminished area under the hydroxylamine plasma concentration-time curve by 65%, apparent formation clearance of the hydroxylamine by 71%, and clearance of dapsone by 26%. Disulfiram produced a 78% lower concentration of methemoglobin 8 hours after dapsone.
引用
收藏
页码:556 / 566
页数:11
相关论文
共 44 条
[1]  
BUHL R, 1989, LANCET, V2, P1294
[2]   HUMAN CYTOCHROME P-450PA (P-450IA2), THE PHENACETIN O-DEETHYLASE, IS PRIMARILY RESPONSIBLE FOR THE HEPATIC 3-DEMETHYLATION OF CAFFEINE AND N-OXIDATION OF CARCINOGENIC ARYLAMINES - (AROMATIC-AMINES HETEROCYCLIC AMINES CARCINOGEN METABOLISM) [J].
BUTLER, MA ;
IWASAKI, M ;
GUENGERICH, FP ;
KADLUBAR, FF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (20) :7696-7700
[3]   THE USE OF CIMETIDINE AS A SELECTIVE INHIBITOR OF DAPSONE N-HYDROXYLATION IN MAN [J].
COLEMAN, MD ;
SCOTT, AK ;
BRECKENRIDGE, AM ;
PARK, BK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (05) :761-767
[4]   THE USE OF CIMETIDINE TO REDUCE DAPSONE-DEPENDENT METHEMOGLOBINEMIA IN DERMATITIS-HERPETIFORMIS PATIENTS [J].
COLEMAN, MD ;
RHODES, LE ;
SCOTT, AK ;
VERBOV, JL ;
FRIEDMANN, PS ;
BRECKENRIDGE, AM ;
PARK, BK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (03) :244-249
[5]   REDUCTION OF DAPSONE HYDROXYLAMINE TO DAPSONE DURING METHEMOGLOBIN FORMATION IN HUMAN ERYTHROCYTES INVITRO [J].
COLEMAN, MD ;
JACOBUS, DP .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (05) :1027-1033
[6]   MICROSOMAL N-OXIDATION OF DAPSONE AS A CAUSE OF METHEMOGLOBIN FORMATION IN HUMAN RED-CELLS [J].
CUCINELL, SA ;
DAYTON, PG ;
ISRAILI, ZH .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1972, 21 (03) :322-+
[7]   RELATIONSHIP BETWEEN PHENYTOIN AND TOLBUTAMIDE HYDROXYLATIONS IN HUMAN LIVER-MICROSOMES [J].
DOECKE, CJ ;
VERONESE, ME ;
POND, SM ;
MINERS, JO ;
BIRKETT, DJ ;
SANSOM, LN ;
MCMANUS, ME .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (02) :125-130
[8]  
Estabrook RW., 1972, METHODS PHARM, Vvol 2, P303
[9]  
FAVREAU LV, 1987, J BIOL CHEM, V262, P14319
[10]  
FLEMING CM, 1992, MOL PHARMACOL, V41, P975